A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 16 Jul 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
- 05 Jun 2018 Results assessing the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (n=70) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 23 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.